Apixaban Discontinuation Before Bronchoscopy
Stop apixaban 48 hours (2 days) before bronchoscopy if transbronchial biopsy or other high-bleeding-risk sampling is planned; stop 24 hours (1 day) before if only low-risk procedures like bronchial washing or simple inspection are planned.
Procedure-Specific Timing
The bleeding risk of the bronchoscopy determines the discontinuation interval:
High Bleeding Risk Procedures (48-hour hold)
- Transbronchial lung biopsy
- Bronchial biopsy (when anticipated)
- Any sampling procedure with moderate-to-high bleeding risk
The FDA label explicitly states that apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 1. This aligns with the 2022 American College of Chest Physicians guideline, which used a standardized approach of interrupting DOACs for 2 days before high-bleed-risk procedures in the landmark PAUSE study 2.
Low Bleeding Risk Procedures (24-hour hold)
- Simple bronchoscopy without biopsy
- Bronchoalveolar lavage alone
- EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration)
The FDA label specifies that apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where bleeding would be non-critical in location and easily controlled 1.
Evidence Supporting This Approach
The PAUSE study prospectively validated this strategy in 1,257 apixaban-treated patients with atrial fibrillation undergoing elective procedures. Using 1-day interruption for low-bleed-risk and 2-days for high-bleed-risk procedures, the 30-day rates were exceptionally low: arterial thromboembolism 0.16% and major bleeding 1.35% 2.
A 2025 real-world study of 75 patients on NOACs (including 36 on apixaban) who underwent bronchoscopy with invasive sampling found that following local protocols for NOAC discontinuation resulted in only mild-to-moderate bleeding in 12% of patients, with no severe bleeding or thromboembolic events 3. This bleeding rate was comparable to patients on aspirin (14.7%) and those on no anticoagulation (9.1%).
Important Caveats and Modifications
Renal Impairment
Extend the discontinuation period by 24 hours if creatinine clearance is <50 mL/min, particularly for high-bleeding-risk procedures. The PAUSE study excluded patients with severe renal insufficiency (CrCl <25 mL/min for apixaban), and the 2022 ACCP guideline notes that patients with CrCl <30 mL/min may require longer interruption intervals 2.
Drug Interactions
If the patient is taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin), consider extending the hold period by 24 hours, as these medications significantly impair apixaban clearance 2, 1.
Bridging Not Required
Do not use bridging anticoagulation (heparin or LMWH) during the 24-48 hour interruption period. The FDA label explicitly states that "bridging anticoagulation during the 24 to 48 hours after stopping apixaban tablets and prior to the intervention is not generally required" 1. The PAUSE study demonstrated safety without bridging 2.
Comparison with Older Guidelines
The 2001 British Thoracic Society guidelines recommend stopping "oral anticoagulants" at least 3 days before bronchoscopy if biopsies are anticipated 4. However, these guidelines predate DOACs and were written for warfarin (vitamin K antagonists), which have much longer half-lives. The 3-day recommendation does not apply to apixaban, which has a half-life of approximately 12 hours and is cleared much faster than warfarin.
Resumption After Procedure
Restart apixaban as soon as adequate hemostasis is established, typically within 24 hours post-procedure if there are no bleeding complications 1. The FDA label emphasizes restarting "as soon as adequate hemostasis has been established" rather than waiting a fixed interval.
Common Pitfalls to Avoid
- Don't apply warfarin guidelines to apixaban: The 3-day hold recommended for warfarin is unnecessarily long for apixaban and increases thromboembolic risk
- Don't use bridging therapy: This increases bleeding risk without reducing thromboembolism
- Don't forget to account for renal function: Apixaban clearance is significantly affected by kidney function
- Don't restart too early: Ensure hemostasis is truly adequate before resuming, especially after transbronchial biopsy where delayed pneumothorax or bleeding can occur